42°20′12″N 87°50′04″W / 42.33679°N 87.83432°W
 | |
 Headquarters | |
| Company type | Public |
|---|---|
| Industry | Biopharmaceutical |
| Founded | April 10, 2012 |
| Headquarters | 1 North Waukegan Road, North Chicago, Illinois, United States |
Area served | 170+ countries worldwide |
Key people | |
| Products | |
| Revenue |  US$54.32 billion (2023) |
| US$12.76 billion (2023) | |
| US$4.873 billion (2023) | |
| Total assets | US$134.7 billion (2023) |
| Total equity | US$10.36 billion (2023) |
Number of employees | c. 50,000 (2024) |
| Website | abbvie |
| Footnotes / references [1]: facepage, 51–55 | |
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. It is ranked sixth on the list of largest biomedical companies by revenue. In 2023, the company's seat in Forbes Global 2000 was 74,[2] and rank 89 on the 2024 list.[3] The company's primary product is Humira (adalimumab) ($14 billion in 2023 revenues, 27 percent of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis.
It developed Skyrizi ($7.8 billion in 2023 revenues), an interleukin-23 (IL-23) inhibitor also used to treat autoimmune diseases. Its other major products include Botox ($5.7 billion in 2023 revenues), Imbruvica to treat cancer ($3.6 billion in 2023 revenues), Rinvoq to treat arthritis ($4 billion in 2023 revenues), Venclexta to treat leukemia and lymphoma ($2.3 billion in 2023 revenues), Vraylar to treat schizophrenia and bipolar disorder ($2.7 billion in 2023 revenues), and Mavyret to treat Hepatitis C ($1.4 billion in 2023 revenues).[1]: 39–40 The company is also committed to product development for other treatments of cancer, neurologic diseases, eye care, and cystic fibrosis.[1]: 34 [4]
In 2023, Humira began facing competition from a biosimilar developed by Amgen. The company is also developing a drug for Parkinson's disease that could be a blockbuster drug in 2027 and is awaiting approval from the Food and Drug Administration for epcoritamab, a blood-cancer therapy under development in partnership with Genmab.[5]
The name "AbbVie" is derived from a combination of "Abbott", the name of its former parent company, with "vie", intended as a reference to a Latin root meaning 'life'.[6]
- ^ a b c "AbbVie Inc. 2023 Annual Report (Form 10-K)". U.S. Securities and Exchange Commission. 20 February 2024.
- ^ Murphy, Andrea; Tucker, Hank, eds. (8 June 2023). "The Global 2000 2023". Forbes. p. 2. Archived from the original on 2024-02-26. Retrieved 2024-02-07.
- ^ Murphy, Andrea; Schifrin, Matt, eds. (6 June 2024). "The Global 2000". Forbes. p. 2. Archived from the original on 29 Jan 2024. Retrieved 29 August 2024.
- ^ Carroll, John (October 25, 2019). "AbbVie doubles down on cystic fibrosis R&D, adding a new drug to the pipeline as Vertex seals its domination of the field with Trikafta OK". EndpointNews. University of Kansas.
- ^ Hopkins, Jared S. (February 6, 2023). "AbbVie Aims for New Drugs to Boost Sales as Competitors Target Humira". The Wall Street Journal.
- ^ "Abbott Selects AbbVie as New Name for Future Research-Based Pharmaceutical Company". Abbott MediaRoom (Press release). March 21, 2012.